Core Viewpoint - The report highlights the strong financial performance of Sepax Technologies, with significant revenue and profit growth driven by the increasing demand for chromatography materials in the biopharmaceutical sector [1][2]. Financial Performance - In the first three quarters of 2025, Sepax Technologies achieved a revenue of 302 million yuan, representing a year-on-year growth of 38.39% [1][2]. - The net profit attributable to shareholders reached 93.21 million yuan, reflecting a high growth rate of 71.07% compared to the previous year [1][2]. - In Q3 alone, the company reported an explosive growth with revenue and net profit increasing by 81.39% and 141.05% year-on-year, respectively [2]. Business Strategy - The company capitalized on the domestic substitution strategy by actively expanding its customer base and enhancing cooperation with existing clients, leading to further business growth [2][3]. - Sepax Technologies has invested 40.60 million yuan in R&D in the first three quarters of 2025, marking a 20.37% increase year-on-year, which strengthens its technological advantages [2]. Market Position and Global Strategy - The chromatography filler market, previously dominated by international giants, is experiencing a shift towards domestic alternatives, with Sepax Technologies transitioning from imitation to parallel competition and even local leadership [3]. - The company has established a global presence since 2002, with a focus on R&D and innovation in chromatography materials, and has set up a production base in the U.S. to support its dual-circulation strategy [3]. Industry Context - The biopharmaceutical sector in China is entering a commercialization phase, with many R&D projects expected to materialize in the next 3-5 years, creating a robust demand for chromatography materials [3][4]. - Sepax Technologies is positioned as a key player in the high-end biopharmaceutical materials sector, contributing to China's global competitiveness in this field [4].
赛分科技前三季度净利高增71% 国产色谱龙头迎来刚性需求下的价值重估